Cover Image

Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors

Abstract

Description

This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma

  • The melanoma report part comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 investigators, from Ceased to Marketed. This part extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma.

Part II: Apoptosis

  • The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.

Part III: Protein Kinase Inhibitors

  • The protein kinase report comprises defined and up to date development strategies for 409 protein kinase drugs (990 projects) within the portfolio of 160 investigators, from Ceased to Marketed. This report part extensively analyses 133 identified targets of protein kinase drugs, organized into 200 drug target strategies, and assesses them in 57 different cancer indications.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

  • Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
  • Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
  • Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
  • Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
  • Supporting development of integrative molecule, pathway and disease area strategies
  • Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Table of Contents

Key Topics Covered:

Part I: Melanoma

  • 5.1. The Scope of this Report
  • 6. Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (170 Drug Targets)
  • 7. Emerging New Products to Established Ones: Drug Target Strategies of Melanoma Drugs by their Highest Stage of Development (151 Drug Target Strategies and 218 Melanoma Drugs)
  • 8. Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (8 Compound Strategies)
  • 9. Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Investigator (138 Companies)
  • 10. Disclaimer
  • 11. Drug Index
  • 12. Company Index
  • Figures: Includes 6 Figures
  • Tables: Includes 196 Tables
  • Total Number of Pages: 777

Part II: Apoptosis

  • 5.1. The Scope of this Report
  • 6. Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)
  • 7. Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs)
  • 8. Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies)
  • 9. Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications)
  • 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs)
  • Disclaimer
  • 11. Drug Index
  • 12. Company Index
  • Figures: Includes 7 Figures
  • Tables: Includes 315 Tables
  • Total Number of Pages: 1,617

Part III: Protein Kinase Inhibitors

  • 5.1. The Scope of this Report
  • 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (133 Drug Targets)
  • 7. The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Protein Kinase Therapeutic Pipeline? (200 Drug Target Strategies and 409 Drugs)
  • 8. Compound Strategies at Work: Competitive Benchmarking of Protein Kinase Drugs in Oncology by Compound Type (7 Compound Strategies)
  • 9. Selecting Cancer Indications for Protein Kinase Therapeutics (57 Different Cancer Indications)
  • 10. Portfolio Planning: Competitive Benchmarking of Protein Kinase Cancer Therapeutic Pipeline by Investigator (160 Investigators)
  • 12. Drug Index
  • 13. Company Index
  • Figures: Includes 6 Figures
  • Tables: Includes 302 Tables
  • Total Number of Pages: 1442

This Report Includes the Following Companies:

  • 3SBio
  • 4SC
  • Abbott
  • Abiogen
  • Abraxis BioScience
  • Access
  • Actelion
  • Adherex
  • Advanced Life Sciences
  • Advaxis
  • Advenchen
  • AEgera
  • AEterna Zentaris
  • Aida Pharmaceuticals
  • Aileron Therapeutics
  • Alethia Biotherapeutics
  • Alfacell
  • Alnylam
  • AlphaVax
  • Altor BioScience
  • Ambit Biosciences
  • Ambrilia Biopharma
  • Amgen
  • Amphora
  • Anadys Pharmaceuticals
  • Anaphore
  • Anavex Life Sciences
  • AngioChem
  • Antisense Pharma
  • Antisoma
  • Aphios
  • Apogenix
  • ApopLogic Pharmaceuticals
  • Apotex
  • Apthera
  • Ariad
  • Arno Therapeutics
  • ArQule
  • Array BioPharma
  • Ascenta Therapeutics
  • Astellas
  • Astex Therapeutics
  • AstraZeneca
  • Attenuon
  • Avila Therapeutics
  • Basilea Pharmaceutica
  • Bayer
  • Benitec
  • Berkeley Lab
  • Bio-Medisinsk Innovasjon
  • BioAlliance Pharma
  • BioAxone
  • Biocad
  • Biogen Idec
  • BioInvent
  • Biokine Therapeutics
  • BioLineRx
  • Biomas
  • Bionovo
  • BioNumerik
  • Biosceptre
  • Biotecnol
  • BioVex
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • BTG
  • Callisto Pharmaceuticals
  • CanBas
  • Cancer Research Technology
  • CDG Therapeutics
  • Celera
  • Celgene
  • Cell Genesys
  • Cell Therapeutics
  • Celldex Therapeutics
  • Celtic Pharma
  • Cephalon
  • ChemoCentryx
  • Chlorogen
  • Chroma Therapeutics
  • CJ Corp
  • Clavis Pharma
  • Cleveland BioLabs
  • CombinatoRx
  • CompleGen
  • Compugen
  • Coronado Biosciences
  • Cosmo Pharmaceuticals
  • Critical Outcome Technologies
  • CSL
  • Curis
  • Cyclacel
  • Cylene Pharmaceuticals
  • Cynvec
  • CytImmune Sciences
  • Cytochroma
  • Cytokinetics
  • CytRx
  • Daewoong
  • Daiichi Sankyo
  • Dainippon Sumitomo Pharma
  • Dara Biosciences
  • Deciphera Pharmaceuticals
  • DeveloGen
  • DNAVEC
  • Dong-A
  • Dyax
  • Eisai
  • Elara Pharmaceuticals
  • Eleos
  • Eli Lilly
  • Emergent BioSolutions
  • Enkam Pharmaceuticals
  • EntreMed
  • Enzon
  • EpiCept
  • Erimos
  • Exelixis
  • Facet Biotech
  • Flamel Technologies
  • Galapagos
  • Genentech
  • Generex
  • Genta
  • GenVec
  • Genzyme
  • Gerolymatos
  • Geron
  • GlaxoSmithKline
  • GlycoGenesys
  • Glycotope
  • GPC Biotech
  • Green Cross
  • Hanmi
  • Harbor BioSciences
  • Hemispherx Biopharma
  • Hoffmann-La Roche
  • Human Genome Sciences
  • Ichor Medical Systems
  • Idera Pharmaceuticals
  • ImClone Systems
  • Immunocore
  • ImmunoFrontier
  • ImmunoGen
  • Immutep
  • Incyte Corporation
  • Infinity Pharmaceuticals
  • Innate Pharma
  • InNexus Biotechnology
  • Inotek
  • Inovio
  • Insmed
  • Insys Therapeutics
  • Intradigm
  • Intrexon
  • Introgen Therapeutics
  • Ipsen
  • Isis Pharmaceuticals
  • ISU ABXIS
  • Jennerex Biotherapeutics
  • Johnson & Johnson
  • KAI Pharmaceuticals
  • Kalypsys
  • Karyon-CTT
  • Keryx Biopharmaceuticals
  • Kiadis
  • Kirin Pharma
  • Kyowa Hakko Kirin
  • Leo
  • LG Life Sciences
  • Ligand
  • Locus Pharmaceuticals
  • Lorus Therapeutics
  • Mannkind
  • MaxoCore Pharmaceuticals
  • MediGene
  • Medisyn Technologies
  • Merck & Co
  • Merck KGaA
  • MethylGene
  • Mitsubishi Tanabe Pharma
  • Mochida
  • Mojave Therapeutics
  • MolMed
  • Mologen
  • NeoPharm
  • Nereus Pharmaceuticals
  • Nerviano Medical Sciences
  • NicOx
  • Nidus Laboratories
  • NIH
  • Nippon Shinyaku
  • Non-industrial source
  • Novacea
  • NovaLead
  • Novartis
  • Novelix
  • Novogen
  • Oncalis
  • Onconova
  • OncoTherapy Science
  • Oncothyreon
  • OSI Pharmaceuticals
  • Oxford BioMedica
  • OXiGENE
  • PanaGin
  • Patrys
  • PBL Therapeutics
  • Peregrine Pharmaceuticals
  • Pfizer
  • Pharmacyclics
  • PharmaGap
  • PharmaMar
  • Pharmexa
  • Pharminox
  • PhiloGene
  • Pierre Fabre
  • Piramal
  • Plexxikon
  • Progen
  • ProMetic Life Sciences
  • QLT
  • Reata Pharmaceuticals
  • Receptor BioLogix
  • Regulon
  • Rexahn
  • Rigel
  • Rosetta Genomics
  • Sanofi
  • Sanofi-Aventis
  • Santaris Pharma
  • Sareum
  • SBI Biotech
  • SBIO
  • Scancell
  • Schering-Plough
  • SciClone Pharmaceuticals
  • Seattle Genetics
  • Semafore Pharmaceuticals
  • Senesco Technologies
  • Shire
  • Sigma-Tau
  • Silence Therapeutics
  • Simcere Pharmaceuticals
  • Solbec Pharmaceuticals
  • Spirogen
  • SRI International
  • SuperGen
  • Supratek Pharma
  • Swedish Orphan Biovitrum
  • Switch Pharma
  • SymBio Pharmaceuticals
  • Symbiotec
  • Takeda
  • Targa Therapeutics
  • TargeGen
  • Targepeutics
  • Taxolog
  • Tekmira Pharmaceuticals
  • Telik
  • TetraLogic Pharmaceuticals
  • Teva
  • Thallion Pharmaceuticals
  • Therion Biologics
  • Theryte
  • Tigris Pharmaceuticals
  • ToolGen
  • TopoTarget
  • Tracon Pharmaceuticals
  • Transgene
  • UCB
  • UMN Pharma
  • ValiRx
  • VasGene Therapeutics
  • VaxOnco
  • VBL Therapeutics
  • Vectura
  • Velacor Therapeutics
  • Vertex Pharmaceuticals
  • Vical
  • VioQuest
  • Viragen
  • Viralytics
  • ViroMed
  • ViroTarg
  • VM Discovery
  • Wyeth
  • Xencor
  • Xerion
  • York Pharma
  • ZymoGenetics

A Shortlist of Drugs Included are:

  • 131I-tositumomab
  • AEG-35156
  • AG-14699
  • agatolimod
  • aldesleukin
  • ALT-801
  • alvocidib
  • AME-133
  • APG-101
  • APO-866
  • ARQ-197
  • AS-101
  • AS-1411
  • astuprotimut-r
  • axitinib
  • bardoxolone methyl
  • belinostat
  • bevacizumab
  • BIBW-2992
  • BMS-663513
  • bortezomib
  • bosentan
  • bosutinib
  • brivanib alaninate
  • BZL-101
  • canfosfamide hydrochloride
  • cediranib
  • cenersen
  • cintredekin besudotox
  • conatumumab
  • cositecan
  • crolibulin
  • dasatinib
  • decitabine
  • deforolimus
  • denenicokin
  • dinaciclib
  • dovitinib lactate
  • dulanermin
  • E-75
  • EMD-273063
  • endostatin
  • entinostat
  • enzastaurin hydrochloride
  • epirubicin
  • erlotinib
  • everolimus
  • Exherin
  • fosbretabulin tromethamine
  • fresolimumab
  • gataparsen
  • gefitinib
  • glembatumumab
  • golnerminogene pradenovec
  • GT-111
  • GV-1001
  • HE-3235
  • histamine dihydrochloride
  • ibritumomab tiuxetan
  • idronoxil
  • imatinib mesilate
  • imetelstat
  • IMP-321
  • INGN-241
  • interferon-alpha
  • interferon-alpha2
  • interferon-alpha2a
  • interferon-alpha2b
  • interferon-beta
  • interleukin-2, 2nd-generation
  • intetumumab
  • IPH-1101
  • ipilimumab
  • ispinesib mesylate
  • JX-594
  • kahalalide F
  • L19-IL2
  • lapatinib ditosylate
  • lestaurtinib
  • LipoVIL12
  • litronesib
  • lonaprisan
  • lumiliximab
  • mapatumumab
  • MDX-1106
  • MetXia
  • MGN-1601
  • midostaurin
  • MKC-1
  • MKC-1106-MT
  • mocetinostat
  • motesanib diphosphate
  • motexafin gadolinium
  • navitoclax
  • nilotinib
  • noscapine
  • obinutuzumab
  • oblimersen sodium
  • ON-01910
  • Oncohist
  • OncoVEX GM-CSF
  • P-276-00
  • panobinostat
  • PAT-SC1
  • pazopanib hydrochloride
  • PBI-1402
  • PCI-24781
  • peginterferon alfa-2b
  • perifosine
  • plitidepsin
  • PLX-4032
  • PX-12
  • quarfloxacin
  • quinacrine
  • R-(-)-gossypol
  • RAF-265
  • ramucirumab
  • retaspimycin
  • sagopilone
  • sargramostim
  • seliciclib
  • selumetinib
  • sodium stibogluconate
  • sorafenib tosylate
  • SPC-2996
  • s-lapachone
  • SU-6668
  • sunitinib malate
  • tanespimycin
  • temsirolimus
  • terameprocol
  • thymalfasin
  • tigapotide triflutate
  • tigatuzumab
  • tipifarnib
  • TL-32711
  • topotecan
  • trabedersen
  • tremelimumab
  • triciribine phosphate
  • TRU-016
  • vandetanib
  • velimogene aliplasmid
  • veliparib
  • volasertib
  • volociximab
  • vosaroxin
  • XL-147
  • XL-184
  • XL-647
  • YM-155
Show More
Pricing